Sanoja-Flores, LFlores-Montero, JGarcés, J JPaiva, BPuig, NGarcía-Mateo, AGarcía-Sánchez, OCorral-Mateos, ABurgos, LBlanco, EHernández-Martín, JPontes, RDíez-Campelo, MMillacoy, PRodríguez-Otero, PProsper, FMerino, JVidriales, M BGarcía-Sanz, RRomero, APalomera, LRíos-Tamayo, RPérez-Andrés, MBlanco, J FGonzález, Mvan Dongen, J J MDurie, BMateos, M VSan-Miguel, JOrfao, AEuroFlow consortium2023-01-252023-01-252018-11-19http://hdl.handle.net/10668/13210Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AdultAgedAged, 80 and overBiomarkersDiagnosis, DifferentialFemaleFlow CytometryHumansImmunophenotypingMaleMiddle AgedMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaNeoplasm StagingNeoplastic Cells, CirculatingPlasma CellsPrognosisSensitivity and Specificityresearch article30455467open access10.1038/s41408-018-0153-92044-5385PMC6242818https://www.nature.com/articles/s41408-018-0153-9.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242818/pdf